Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antibodies, Viral | 138 | 2024 | 3177 | 13.500 |
Why?
|
Immunity, Humoral | 57 | 2024 | 598 | 12.270 |
Why?
|
HIV Antibodies | 63 | 2023 | 1322 | 11.840 |
Why?
|
Antibodies, Neutralizing | 108 | 2023 | 1978 | 9.770 |
Why?
|
Immunoglobulin Fc Fragments | 36 | 2023 | 279 | 8.810 |
Why?
|
AIDS Vaccines | 44 | 2023 | 938 | 7.640 |
Why?
|
HIV-1 | 114 | 2023 | 6939 | 7.470 |
Why?
|
Immunoglobulin G | 92 | 2023 | 4561 | 7.250 |
Why?
|
Killer Cells, Natural | 53 | 2023 | 2133 | 6.730 |
Why?
|
HIV Infections | 146 | 2024 | 16715 | 6.300 |
Why?
|
Receptors, Fc | 25 | 2023 | 541 | 5.280 |
Why?
|
Ebolavirus | 17 | 2023 | 263 | 4.220 |
Why?
|
Antibodies | 21 | 2023 | 2460 | 4.210 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 25 | 2021 | 307 | 4.090 |
Why?
|
HIV | 24 | 2022 | 1604 | 4.050 |
Why?
|
Vaccination | 50 | 2024 | 3279 | 4.030 |
Why?
|
Hemorrhagic Fever, Ebola | 18 | 2023 | 428 | 3.910 |
Why?
|
Phagocytosis | 28 | 2022 | 1539 | 3.680 |
Why?
|
Antibodies, Bacterial | 14 | 2023 | 1470 | 3.650 |
Why?
|
Viral Vaccines | 19 | 2023 | 636 | 3.570 |
Why?
|
Receptors, IgG | 25 | 2023 | 582 | 3.340 |
Why?
|
Vaccines | 15 | 2023 | 823 | 3.260 |
Why?
|
Influenza Vaccines | 10 | 2024 | 738 | 3.250 |
Why?
|
Latent Tuberculosis | 7 | 2022 | 225 | 3.180 |
Why?
|
Immunity, Innate | 31 | 2021 | 2962 | 3.120 |
Why?
|
Tuberculosis | 16 | 2023 | 1912 | 2.910 |
Why?
|
Mycobacterium tuberculosis | 16 | 2023 | 1832 | 2.880 |
Why?
|
Antibody Formation | 16 | 2023 | 1402 | 2.850 |
Why?
|
Viral Load | 42 | 2021 | 3300 | 2.720 |
Why?
|
Simian immunodeficiency virus | 22 | 2022 | 846 | 2.680 |
Why?
|
HIV Antigens | 9 | 2021 | 347 | 2.580 |
Why?
|
Immunoglobulin Fab Fragments | 7 | 2021 | 482 | 2.540 |
Why?
|
Glycosylation | 24 | 2022 | 1128 | 2.410 |
Why?
|
Polysaccharides | 14 | 2022 | 1059 | 2.400 |
Why?
|
Receptors, KIR | 15 | 2016 | 113 | 2.390 |
Why?
|
Influenza, Human | 8 | 2024 | 1479 | 2.330 |
Why?
|
Immunization, Passive | 9 | 2022 | 623 | 2.320 |
Why?
|
Virus Replication | 21 | 2021 | 2535 | 2.120 |
Why?
|
Macaca mulatta | 47 | 2023 | 2377 | 2.040 |
Why?
|
Malaria Vaccines | 5 | 2024 | 158 | 2.010 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 17 | 2021 | 570 | 1.960 |
Why?
|
Immunoglobulin A | 11 | 2023 | 995 | 1.830 |
Why?
|
SAIDS Vaccines | 9 | 2020 | 166 | 1.800 |
Why?
|
Antibodies, Monoclonal | 29 | 2023 | 9274 | 1.700 |
Why?
|
Cross Reactions | 12 | 2022 | 841 | 1.650 |
Why?
|
High-Throughput Screening Assays | 7 | 2021 | 944 | 1.650 |
Why?
|
Immunoglobulin M | 11 | 2023 | 1537 | 1.630 |
Why?
|
CD4-Positive T-Lymphocytes | 38 | 2023 | 4386 | 1.580 |
Why?
|
Primates | 9 | 2023 | 545 | 1.560 |
Why?
|
Viremia | 17 | 2022 | 736 | 1.550 |
Why?
|
Immunity | 10 | 2023 | 1014 | 1.540 |
Why?
|
Pregnancy Complications, Infectious | 9 | 2022 | 2026 | 1.540 |
Why?
|
Ebola Vaccines | 4 | 2023 | 24 | 1.510 |
Why?
|
Histocompatibility Antigens Class I | 14 | 2022 | 1366 | 1.500 |
Why?
|
Humans | 369 | 2024 | 744366 | 1.470 |
Why?
|
Placenta | 9 | 2022 | 1699 | 1.460 |
Why?
|
Orthomyxoviridae | 2 | 2024 | 156 | 1.450 |
Why?
|
Antigen-Antibody Complex | 6 | 2022 | 517 | 1.440 |
Why?
|
HIV Envelope Protein gp120 | 11 | 2020 | 952 | 1.410 |
Why?
|
Coronavirus Infections | 11 | 2020 | 3135 | 1.360 |
Why?
|
Pneumonia, Viral | 11 | 2020 | 3242 | 1.350 |
Why?
|
Malaria | 4 | 2023 | 1239 | 1.320 |
Why?
|
Milk, Human | 4 | 2021 | 490 | 1.300 |
Why?
|
Adjuvants, Immunologic | 10 | 2021 | 1000 | 1.270 |
Why?
|
Lymphocyte Subsets | 5 | 2016 | 315 | 1.240 |
Why?
|
Malaria, Falciparum | 5 | 2024 | 1077 | 1.240 |
Why?
|
B-Lymphocytes | 21 | 2023 | 4666 | 1.220 |
Why?
|
Complement System Proteins | 8 | 2021 | 795 | 1.160 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 8 | 2020 | 371 | 1.160 |
Why?
|
Epitopes | 23 | 2022 | 2571 | 1.160 |
Why?
|
CD8-Positive T-Lymphocytes | 27 | 2022 | 4479 | 1.150 |
Why?
|
Host-Pathogen Interactions | 15 | 2022 | 1480 | 1.140 |
Why?
|
Animals | 124 | 2023 | 168768 | 1.040 |
Why?
|
Respiratory Syncytial Virus Vaccines | 2 | 2023 | 32 | 1.030 |
Why?
|
Monocytes | 13 | 2022 | 2596 | 1.020 |
Why?
|
Saponins | 2 | 2021 | 50 | 1.010 |
Why?
|
Immune System | 4 | 2018 | 806 | 0.980 |
Why?
|
HIV Core Protein p24 | 5 | 2020 | 256 | 0.980 |
Why?
|
Antigens, Viral | 13 | 2023 | 1035 | 0.970 |
Why?
|
Antigens, Bacterial | 6 | 2023 | 1172 | 0.970 |
Why?
|
Immune Evasion | 6 | 2016 | 360 | 0.950 |
Why?
|
Viral Envelope Proteins | 12 | 2022 | 636 | 0.920 |
Why?
|
Adaptive Immunity | 7 | 2023 | 714 | 0.900 |
Why?
|
Lymphocyte Activation | 21 | 2020 | 5524 | 0.890 |
Why?
|
Immunity, Cellular | 17 | 2023 | 1607 | 0.890 |
Why?
|
Neutrophils | 10 | 2023 | 3721 | 0.880 |
Why?
|
Vaccines, DNA | 6 | 2021 | 305 | 0.880 |
Why?
|
Antibody Affinity | 8 | 2021 | 254 | 0.870 |
Why?
|
Immunity, Maternally-Acquired | 2 | 2020 | 118 | 0.870 |
Why?
|
Rubella | 1 | 2022 | 48 | 0.850 |
Why?
|
RNA, Viral | 16 | 2022 | 2901 | 0.850 |
Why?
|
Shigella | 1 | 2022 | 74 | 0.820 |
Why?
|
Immunologic Techniques | 2 | 2019 | 219 | 0.820 |
Why?
|
Dysentery, Bacillary | 1 | 2022 | 75 | 0.820 |
Why?
|
Adenoviridae | 6 | 2021 | 1101 | 0.820 |
Why?
|
Alphavirus | 4 | 2023 | 9 | 0.820 |
Why?
|
Virus Latency | 4 | 2021 | 358 | 0.790 |
Why?
|
Nucleocapsid Proteins | 2 | 2023 | 77 | 0.790 |
Why?
|
HLA-C Antigens | 3 | 2016 | 147 | 0.780 |
Why?
|
Squalene | 2 | 2021 | 32 | 0.780 |
Why?
|
Complement Activation | 3 | 2019 | 453 | 0.780 |
Why?
|
Respiratory Syncytial Virus Infections | 2 | 2023 | 329 | 0.760 |
Why?
|
Vaccines, Synthetic | 13 | 2023 | 634 | 0.750 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 10 | 2023 | 3873 | 0.750 |
Why?
|
BCG Vaccine | 3 | 2023 | 369 | 0.740 |
Why?
|
Respiratory Syncytial Virus, Human | 2 | 2023 | 139 | 0.740 |
Why?
|
Systems Analysis | 2 | 2022 | 172 | 0.740 |
Why?
|
Antigens | 8 | 2022 | 1466 | 0.730 |
Why?
|
Polysorbates | 1 | 2020 | 41 | 0.730 |
Why?
|
Female | 134 | 2023 | 380193 | 0.710 |
Why?
|
Plasma | 3 | 2022 | 575 | 0.700 |
Why?
|
Genetic Vectors | 11 | 2023 | 3424 | 0.690 |
Why?
|
Electrophoresis, Capillary | 2 | 2020 | 64 | 0.690 |
Why?
|
Interferon-gamma | 21 | 2023 | 3207 | 0.690 |
Why?
|
Antigen-Antibody Reactions | 1 | 2019 | 363 | 0.680 |
Why?
|
HLA Antigens | 6 | 2014 | 1382 | 0.670 |
Why?
|
Immunoassay | 6 | 2021 | 752 | 0.670 |
Why?
|
Influenza A Virus, H5N1 Subtype | 1 | 2020 | 113 | 0.670 |
Why?
|
Tuberculosis Vaccines | 1 | 2019 | 50 | 0.660 |
Why?
|
Flow Cytometry | 20 | 2019 | 5974 | 0.660 |
Why?
|
Acquired Immunodeficiency Syndrome | 8 | 2016 | 2232 | 0.660 |
Why?
|
Antibodies, Protozoan | 5 | 2024 | 253 | 0.660 |
Why?
|
Maternal-Fetal Exchange | 1 | 2020 | 456 | 0.650 |
Why?
|
Tuberculosis, Pulmonary | 2 | 2023 | 810 | 0.650 |
Why?
|
Serology | 1 | 2017 | 7 | 0.640 |
Why?
|
Yellow Fever Vaccine | 1 | 2018 | 37 | 0.630 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 738 | 0.630 |
Why?
|
Pandemics | 19 | 2023 | 8385 | 0.630 |
Why?
|
Antigens, CD | 9 | 2020 | 4026 | 0.630 |
Why?
|
Receptors, KIR3DS1 | 4 | 2016 | 9 | 0.620 |
Why?
|
Pneumococcal Infections | 1 | 2022 | 497 | 0.610 |
Why?
|
Fetal Blood | 2 | 2021 | 1318 | 0.600 |
Why?
|
Systems Biology | 2 | 2018 | 469 | 0.590 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2021 | 1320 | 0.590 |
Why?
|
Alleles | 10 | 2022 | 6933 | 0.580 |
Why?
|
Gene Products, env | 5 | 2020 | 263 | 0.580 |
Why?
|
Membrane Glycoproteins | 10 | 2022 | 3771 | 0.580 |
Why?
|
Phagocytes | 3 | 2019 | 297 | 0.580 |
Why?
|
Streptococcus pneumoniae | 1 | 2022 | 714 | 0.580 |
Why?
|
Nucleocapsid | 5 | 2023 | 59 | 0.580 |
Why?
|
Rheumatic Diseases | 1 | 2023 | 593 | 0.580 |
Why?
|
Antigen Presentation | 3 | 2019 | 1284 | 0.570 |
Why?
|
Carrier State | 2 | 2021 | 518 | 0.570 |
Why?
|
Cell Degranulation | 4 | 2019 | 287 | 0.560 |
Why?
|
Virus Diseases | 3 | 2020 | 711 | 0.560 |
Why?
|
Antibodies, Blocking | 2 | 2014 | 253 | 0.560 |
Why?
|
Inflammation | 9 | 2023 | 10637 | 0.560 |
Why?
|
Receptors, KIR3DL1 | 4 | 2012 | 22 | 0.560 |
Why?
|
Protein Processing, Post-Translational | 3 | 2020 | 1988 | 0.560 |
Why?
|
T-Lymphocytes, Helper-Inducer | 7 | 2022 | 985 | 0.560 |
Why?
|
Immunization | 7 | 2020 | 1256 | 0.560 |
Why?
|
Adult | 78 | 2024 | 214052 | 0.550 |
Why?
|
Antibody Specificity | 7 | 2021 | 1095 | 0.550 |
Why?
|
Male | 107 | 2023 | 350115 | 0.550 |
Why?
|
Toll-Like Receptor 7 | 5 | 2018 | 172 | 0.540 |
Why?
|
Dendritic Cells | 8 | 2015 | 2725 | 0.540 |
Why?
|
AIDS Serodiagnosis | 1 | 2017 | 184 | 0.530 |
Why?
|
Evolution, Molecular | 3 | 2015 | 1939 | 0.530 |
Why?
|
Young Adult | 37 | 2024 | 56429 | 0.530 |
Why?
|
Immunoglobulin Isotypes | 3 | 2021 | 158 | 0.520 |
Why?
|
Glycoproteins | 8 | 2023 | 2266 | 0.520 |
Why?
|
RNA, Messenger | 14 | 2024 | 13035 | 0.520 |
Why?
|
HLA-B Antigens | 3 | 2013 | 354 | 0.500 |
Why?
|
Cytokines | 17 | 2023 | 7323 | 0.500 |
Why?
|
Vaccinia virus | 7 | 2023 | 349 | 0.500 |
Why?
|
Systemic Inflammatory Response Syndrome | 5 | 2023 | 612 | 0.480 |
Why?
|
Chikungunya virus | 4 | 2023 | 50 | 0.480 |
Why?
|
Cell Separation | 4 | 2016 | 1751 | 0.470 |
Why?
|
Immunization, Secondary | 6 | 2022 | 340 | 0.470 |
Why?
|
Guinea Pigs | 9 | 2023 | 1386 | 0.470 |
Why?
|
Mice, Inbred BALB C | 12 | 2021 | 6386 | 0.470 |
Why?
|
CA-125 Antigen | 1 | 2016 | 286 | 0.460 |
Why?
|
Pregnancy | 19 | 2022 | 29144 | 0.460 |
Why?
|
Cytotoxicity, Immunologic | 6 | 2018 | 1369 | 0.450 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2015 | 1821 | 0.450 |
Why?
|
Anti-Retroviral Agents | 11 | 2023 | 1714 | 0.440 |
Why?
|
Cohort Studies | 23 | 2022 | 40559 | 0.440 |
Why?
|
Infant, Premature | 1 | 2022 | 2045 | 0.440 |
Why?
|
Receptors, Complement 3d | 1 | 2013 | 118 | 0.430 |
Why?
|
Communicable Diseases | 2 | 2023 | 880 | 0.430 |
Why?
|
Infant, Newborn | 16 | 2022 | 25628 | 0.430 |
Why?
|
Middle Aged | 56 | 2024 | 213390 | 0.430 |
Why?
|
Alum Compounds | 4 | 2021 | 33 | 0.420 |
Why?
|
Lactation | 4 | 2022 | 412 | 0.420 |
Why?
|
Protein Binding | 15 | 2022 | 9384 | 0.420 |
Why?
|
Neutralization Tests | 5 | 2022 | 758 | 0.410 |
Why?
|
Immunophenotyping | 7 | 2021 | 1880 | 0.410 |
Why?
|
Disease Models, Animal | 23 | 2021 | 18034 | 0.410 |
Why?
|
Hemagglutinins | 2 | 2024 | 117 | 0.400 |
Why?
|
Bacterial Infections | 1 | 2020 | 1401 | 0.400 |
Why?
|
Neutrophil Activation | 3 | 2021 | 186 | 0.390 |
Why?
|
Mice | 40 | 2023 | 81201 | 0.390 |
Why?
|
Genotype | 8 | 2021 | 12952 | 0.380 |
Why?
|
South Africa | 8 | 2023 | 1731 | 0.380 |
Why?
|
Immunologic Memory | 7 | 2022 | 1348 | 0.380 |
Why?
|
Lymphocyte Count | 6 | 2012 | 793 | 0.370 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2012 | 437 | 0.370 |
Why?
|
Protein Engineering | 3 | 2021 | 538 | 0.370 |
Why?
|
Matrix Metalloproteinases | 2 | 2010 | 391 | 0.360 |
Why?
|
Vaccines, Conjugate | 2 | 2022 | 333 | 0.360 |
Why?
|
Sex Characteristics | 2 | 2018 | 2585 | 0.360 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2023 | 157 | 0.360 |
Why?
|
Child | 27 | 2023 | 77709 | 0.360 |
Why?
|
Ligands | 7 | 2016 | 3282 | 0.350 |
Why?
|
Plasmodium falciparum | 5 | 2024 | 1732 | 0.350 |
Why?
|
Marburgvirus | 2 | 2020 | 20 | 0.350 |
Why?
|
Adolescent | 26 | 2024 | 85779 | 0.350 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 4 | 2014 | 27 | 0.340 |
Why?
|
Hepatitis C, Chronic | 3 | 2015 | 1031 | 0.340 |
Why?
|
Models, Immunological | 5 | 2018 | 527 | 0.340 |
Why?
|
Intestinal Mucosa | 3 | 2021 | 3037 | 0.340 |
Why?
|
Macaca | 5 | 2023 | 440 | 0.330 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 805 | 0.330 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2021 | 370 | 0.310 |
Why?
|
Epitope Mapping | 5 | 2021 | 311 | 0.310 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 3 | 2014 | 91 | 0.310 |
Why?
|
Immunoglobulin Constant Regions | 3 | 2017 | 60 | 0.310 |
Why?
|
Viral Proteins | 5 | 2021 | 1900 | 0.310 |
Why?
|
Infant | 16 | 2024 | 35134 | 0.300 |
Why?
|
Carbohydrate Sequence | 2 | 2018 | 414 | 0.300 |
Why?
|
Ferrets | 4 | 2023 | 194 | 0.290 |
Why?
|
Toll-Like Receptors | 4 | 2021 | 593 | 0.290 |
Why?
|
HIV Envelope Protein gp41 | 3 | 2020 | 314 | 0.290 |
Why?
|
Adoptive Transfer | 5 | 2021 | 844 | 0.290 |
Why?
|
Autoimmune Diseases | 2 | 2018 | 2134 | 0.290 |
Why?
|
HIV Seropositivity | 4 | 2024 | 971 | 0.290 |
Why?
|
Gene Expression | 9 | 2021 | 7798 | 0.280 |
Why?
|
Immunologic Factors | 4 | 2021 | 1580 | 0.280 |
Why?
|
Case-Control Studies | 13 | 2021 | 21748 | 0.280 |
Why?
|
T-Lymphocyte Subsets | 6 | 2021 | 1837 | 0.280 |
Why?
|
Gene Products, gag | 3 | 2020 | 337 | 0.280 |
Why?
|
Influenza A virus | 2 | 2020 | 456 | 0.280 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2022 | 570 | 0.280 |
Why?
|
Germinal Center | 2 | 2020 | 377 | 0.270 |
Why?
|
Cell Line | 14 | 2021 | 16000 | 0.270 |
Why?
|
DNA, Viral | 5 | 2021 | 2227 | 0.270 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2019 | 693 | 0.270 |
Why?
|
Serum | 2 | 2020 | 214 | 0.270 |
Why?
|
Time Factors | 16 | 2022 | 40075 | 0.270 |
Why?
|
K562 Cells | 5 | 2012 | 635 | 0.260 |
Why?
|
HIV Long-Term Survivors | 3 | 2017 | 126 | 0.260 |
Why?
|
Leukocytes, Mononuclear | 8 | 2021 | 1837 | 0.260 |
Why?
|
Cricetinae | 4 | 2022 | 2475 | 0.260 |
Why?
|
Tuberculin Test | 3 | 2023 | 214 | 0.260 |
Why?
|
Vaccines, Inactivated | 2 | 2024 | 184 | 0.260 |
Why?
|
Human Immunodeficiency Virus Proteins | 3 | 2015 | 65 | 0.260 |
Why?
|
Aged | 21 | 2023 | 163288 | 0.250 |
Why?
|
Macrophage Activation | 2 | 2019 | 560 | 0.250 |
Why?
|
Disease Progression | 12 | 2023 | 13286 | 0.250 |
Why?
|
Virus Release | 2 | 2021 | 39 | 0.250 |
Why?
|
Severity of Illness Index | 9 | 2021 | 15535 | 0.250 |
Why?
|
Adaptation, Physiological | 1 | 2011 | 1312 | 0.250 |
Why?
|
Interleukin-10 | 1 | 2010 | 1200 | 0.250 |
Why?
|
Hepatitis C | 2 | 2014 | 1591 | 0.240 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2006 | 431 | 0.240 |
Why?
|
Antigens, Protozoan | 2 | 2023 | 322 | 0.240 |
Why?
|
Up-Regulation | 5 | 2023 | 4222 | 0.240 |
Why?
|
Vero Cells | 6 | 2021 | 485 | 0.240 |
Why?
|
Liver | 3 | 2021 | 7475 | 0.240 |
Why?
|
Arenaviridae | 1 | 2023 | 5 | 0.240 |
Why?
|
Aging | 3 | 2023 | 8664 | 0.240 |
Why?
|
Mesocricetus | 2 | 2021 | 252 | 0.240 |
Why?
|
Antibody-Dependent Enhancement | 2 | 2020 | 16 | 0.240 |
Why?
|
Uganda | 2 | 2019 | 1237 | 0.240 |
Why?
|
Research Personnel | 1 | 2009 | 573 | 0.230 |
Why?
|
Merozoite Surface Protein 1 | 1 | 2023 | 38 | 0.230 |
Why?
|
Cell Communication | 1 | 2011 | 1621 | 0.230 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily C | 2 | 2014 | 32 | 0.230 |
Why?
|
Merozoites | 1 | 2023 | 64 | 0.230 |
Why?
|
Amino Acid Sequence | 13 | 2021 | 13814 | 0.230 |
Why?
|
Alphavirus Infections | 2 | 2021 | 17 | 0.230 |
Why?
|
Survivors | 4 | 2021 | 2291 | 0.230 |
Why?
|
Vaccines, Subunit | 2 | 2021 | 168 | 0.230 |
Why?
|
Gene Products, pol | 2 | 2020 | 47 | 0.230 |
Why?
|
HEK293 Cells | 7 | 2021 | 4208 | 0.220 |
Why?
|
Viral Regulatory and Accessory Proteins | 2 | 2015 | 159 | 0.220 |
Why?
|
Filoviridae | 3 | 2019 | 16 | 0.220 |
Why?
|
Smallpox Vaccine | 1 | 2023 | 80 | 0.220 |
Why?
|
Lassa virus | 1 | 2023 | 97 | 0.220 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 2 | 2014 | 82 | 0.220 |
Why?
|
Schistosomiasis mansoni | 1 | 2023 | 85 | 0.220 |
Why?
|
Hepatitis D | 1 | 2022 | 18 | 0.220 |
Why?
|
Belgium | 2 | 2019 | 103 | 0.220 |
Why?
|
Endemic Diseases | 1 | 2023 | 182 | 0.220 |
Why?
|
Cell Membrane | 3 | 2015 | 3749 | 0.210 |
Why?
|
Vaccines, Attenuated | 1 | 2024 | 342 | 0.210 |
Why?
|
Anti-HIV Agents | 4 | 2022 | 4255 | 0.210 |
Why?
|
Lymph Nodes | 4 | 2021 | 3476 | 0.210 |
Why?
|
Mucous Membrane | 2 | 2016 | 673 | 0.210 |
Why?
|
Viral Fusion Proteins | 2 | 2023 | 96 | 0.210 |
Why?
|
Virion | 2 | 2021 | 433 | 0.210 |
Why?
|
Chiroptera | 1 | 2023 | 107 | 0.210 |
Why?
|
Single-Chain Antibodies | 1 | 2022 | 108 | 0.210 |
Why?
|
Reproducibility of Results | 5 | 2020 | 19905 | 0.210 |
Why?
|
Coronavirus OC43, Human | 1 | 2021 | 18 | 0.210 |
Why?
|
Vaccinia | 1 | 2022 | 76 | 0.210 |
Why?
|
Sensitivity and Specificity | 7 | 2023 | 14723 | 0.200 |
Why?
|
Lymph | 1 | 2021 | 80 | 0.200 |
Why?
|
Immunodominant Epitopes | 3 | 2019 | 267 | 0.200 |
Why?
|
Immunotherapy | 3 | 2023 | 4446 | 0.200 |
Why?
|
Child, Preschool | 10 | 2024 | 41005 | 0.200 |
Why?
|
Phosphoproteins | 2 | 2020 | 2441 | 0.200 |
Why?
|
Placebos | 3 | 2022 | 1676 | 0.200 |
Why?
|
Stearic Acids | 1 | 2021 | 53 | 0.200 |
Why?
|
Shigella flexneri | 1 | 2022 | 132 | 0.200 |
Why?
|
Chromatography, Affinity | 2 | 2023 | 549 | 0.190 |
Why?
|
Tuberculin | 1 | 2020 | 66 | 0.190 |
Why?
|
Peptides | 4 | 2011 | 4410 | 0.190 |
Why?
|
Conserved Sequence | 3 | 2021 | 1202 | 0.190 |
Why?
|
Typhoid-Paratyphoid Vaccines | 1 | 2021 | 39 | 0.190 |
Why?
|
Injections, Intramuscular | 2 | 2020 | 552 | 0.190 |
Why?
|
T-Lymphocytes | 9 | 2021 | 10183 | 0.190 |
Why?
|
Marburg Virus Disease | 1 | 2020 | 11 | 0.190 |
Why?
|
Perforin | 2 | 2014 | 168 | 0.190 |
Why?
|
Hinge Exons | 1 | 2020 | 2 | 0.190 |
Why?
|
Seroepidemiologic Studies | 4 | 2023 | 402 | 0.190 |
Why?
|
Autoantibodies | 3 | 2023 | 2036 | 0.180 |
Why?
|
Iceland | 1 | 2020 | 183 | 0.180 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 164 | 0.180 |
Why?
|
Dengue Virus | 1 | 2022 | 204 | 0.180 |
Why?
|
Measles | 1 | 2022 | 168 | 0.180 |
Why?
|
Receptors, Complement | 1 | 2021 | 264 | 0.180 |
Why?
|
Haptoglobins | 1 | 2021 | 165 | 0.180 |
Why?
|
Endogenous Retroviruses | 1 | 2021 | 112 | 0.180 |
Why?
|
Asymptomatic Infections | 1 | 2021 | 128 | 0.180 |
Why?
|
Binding Sites | 6 | 2019 | 6111 | 0.180 |
Why?
|
HL-60 Cells | 1 | 2020 | 365 | 0.180 |
Why?
|
Drug Discovery | 2 | 2020 | 1058 | 0.180 |
Why?
|
HIV Integrase Inhibitors | 1 | 2022 | 142 | 0.180 |
Why?
|
Interleukins | 4 | 2021 | 791 | 0.180 |
Why?
|
Th1 Cells | 2 | 2019 | 1057 | 0.180 |
Why?
|
Prospective Studies | 12 | 2023 | 53290 | 0.180 |
Why?
|
Recombinant Proteins | 5 | 2019 | 6621 | 0.180 |
Why?
|
Th2 Cells | 2 | 2019 | 1061 | 0.180 |
Why?
|
Immunoglobulin Class Switching | 1 | 2021 | 291 | 0.180 |
Why?
|
Acute Disease | 9 | 2023 | 7147 | 0.170 |
Why?
|
Bacterial Proteins | 3 | 2022 | 3854 | 0.170 |
Why?
|
Blood Donors | 1 | 2021 | 355 | 0.170 |
Why?
|
Herpesvirus 4, Human | 3 | 2022 | 1041 | 0.170 |
Why?
|
Sierra Leone | 1 | 2020 | 166 | 0.170 |
Why?
|
Serologic Tests | 1 | 2021 | 374 | 0.170 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2021 | 215 | 0.170 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2021 | 222 | 0.170 |
Why?
|
Antiretroviral Therapy, Highly Active | 5 | 2011 | 1872 | 0.170 |
Why?
|
Immunoglobulin Fragments | 1 | 2019 | 84 | 0.170 |
Why?
|
Typhoid Fever | 1 | 2021 | 197 | 0.170 |
Why?
|
Disease Reservoirs | 1 | 2019 | 131 | 0.170 |
Why?
|
HIV Envelope Protein gp160 | 1 | 2019 | 99 | 0.170 |
Why?
|
Models, Molecular | 3 | 2019 | 5451 | 0.170 |
Why?
|
Dengue | 1 | 2022 | 256 | 0.170 |
Why?
|
Cells, Cultured | 14 | 2020 | 19233 | 0.170 |
Why?
|
Antiphospholipid Syndrome | 1 | 2020 | 173 | 0.170 |
Why?
|
Space Flight | 1 | 2021 | 188 | 0.170 |
Why?
|
Viral Nonstructural Proteins | 1 | 2020 | 241 | 0.170 |
Why?
|
Computational Biology | 4 | 2020 | 3519 | 0.170 |
Why?
|
Membrane Proteins | 1 | 2016 | 7882 | 0.170 |
Why?
|
Lymphocytic Choriomeningitis | 2 | 2016 | 132 | 0.170 |
Why?
|
Acyltransferases | 1 | 2020 | 294 | 0.170 |
Why?
|
Receptors, CCR5 | 3 | 2019 | 498 | 0.160 |
Why?
|
Neuraminidase | 1 | 2019 | 210 | 0.160 |
Why?
|
Complement Fixation Tests | 1 | 2018 | 78 | 0.160 |
Why?
|
Pneumococcal Vaccines | 1 | 2022 | 391 | 0.160 |
Why?
|
Drug Administration Routes | 1 | 2018 | 153 | 0.160 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2022 | 547 | 0.160 |
Why?
|
Lung | 6 | 2023 | 9857 | 0.160 |
Why?
|
Carbohydrates | 1 | 2020 | 394 | 0.160 |
Why?
|
Receptors, KIR2DL3 | 2 | 2015 | 17 | 0.160 |
Why?
|
Sialic Acids | 1 | 2018 | 128 | 0.160 |
Why?
|
Pregnancy Trimester, Third | 1 | 2020 | 571 | 0.160 |
Why?
|
Antibody Diversity | 1 | 2017 | 74 | 0.160 |
Why?
|
Fucose | 1 | 2018 | 126 | 0.150 |
Why?
|
Seasons | 1 | 2024 | 1493 | 0.150 |
Why?
|
Microspheres | 3 | 2018 | 777 | 0.150 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 3 | 2011 | 26 | 0.150 |
Why?
|
Mice, Inbred C57BL | 10 | 2021 | 21833 | 0.150 |
Why?
|
Technology, Pharmaceutical | 1 | 2018 | 84 | 0.150 |
Why?
|
Chronic Disease | 12 | 2016 | 9145 | 0.150 |
Why?
|
Trust | 1 | 2022 | 505 | 0.150 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2012 | 15520 | 0.150 |
Why?
|
Respiratory Mucosa | 1 | 2020 | 427 | 0.150 |
Why?
|
Epitopes, T-Lymphocyte | 6 | 2018 | 880 | 0.150 |
Why?
|
Protein Array Analysis | 2 | 2016 | 411 | 0.150 |
Why?
|
Hospitalization | 4 | 2021 | 10259 | 0.150 |
Why?
|
Galactose | 1 | 2018 | 306 | 0.150 |
Why?
|
Tumor Necrosis Factor-alpha | 7 | 2022 | 4424 | 0.150 |
Why?
|
Protein Precursors | 1 | 2021 | 1154 | 0.150 |
Why?
|
Gene Frequency | 3 | 2016 | 3587 | 0.150 |
Why?
|
Bayes Theorem | 3 | 2022 | 2307 | 0.140 |
Why?
|
Cricetulus | 2 | 2018 | 818 | 0.140 |
Why?
|
Arthritis, Experimental | 1 | 2019 | 291 | 0.140 |
Why?
|
Vibrio cholerae | 1 | 2023 | 807 | 0.140 |
Why?
|
Infectious Mononucleosis | 1 | 2016 | 131 | 0.140 |
Why?
|
Cholera | 1 | 2023 | 785 | 0.140 |
Why?
|
CD4 Lymphocyte Count | 6 | 2023 | 2560 | 0.140 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2019 | 659 | 0.140 |
Why?
|
RNA Virus Infections | 1 | 2015 | 17 | 0.140 |
Why?
|
Burkitt Lymphoma | 1 | 2018 | 327 | 0.140 |
Why?
|
Viral Matrix Proteins | 1 | 2016 | 186 | 0.130 |
Why?
|
Organ Specificity | 1 | 2021 | 2008 | 0.130 |
Why?
|
Drug Design | 2 | 2015 | 1076 | 0.130 |
Why?
|
Administration, Inhalation | 1 | 2018 | 1105 | 0.130 |
Why?
|
Immunocompromised Host | 1 | 2020 | 847 | 0.130 |
Why?
|
Down-Regulation | 3 | 2015 | 3001 | 0.130 |
Why?
|
Serine Endopeptidases | 1 | 2020 | 1073 | 0.130 |
Why?
|
Myocarditis | 1 | 2023 | 771 | 0.130 |
Why?
|
Chemokine CXCL13 | 1 | 2015 | 54 | 0.130 |
Why?
|
B-Lymphocyte Subsets | 1 | 2016 | 246 | 0.130 |
Why?
|
Central Nervous System | 1 | 2022 | 1357 | 0.130 |
Why?
|
Antigenic Modulation | 1 | 2014 | 11 | 0.130 |
Why?
|
Transcription, Genetic | 4 | 2015 | 7721 | 0.130 |
Why?
|
Levonorgestrel | 1 | 2015 | 77 | 0.130 |
Why?
|
Interferon-alpha | 3 | 2015 | 895 | 0.120 |
Why?
|
Neoplasms | 3 | 2023 | 21696 | 0.120 |
Why?
|
Blood Bactericidal Activity | 1 | 2014 | 126 | 0.120 |
Why?
|
Nanoparticles | 3 | 2021 | 1905 | 0.120 |
Why?
|
Mucus | 1 | 2016 | 321 | 0.120 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2015 | 163 | 0.120 |
Why?
|
Blood Proteins | 1 | 2019 | 1124 | 0.120 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2015 | 113 | 0.120 |
Why?
|
Receptors, Virus | 1 | 2018 | 649 | 0.120 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 2016 | 329 | 0.120 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2015 | 1572 | 0.120 |
Why?
|
Bronchoalveolar Lavage Fluid | 3 | 2021 | 768 | 0.120 |
Why?
|
Age of Onset | 1 | 2021 | 3270 | 0.120 |
Why?
|
Microscopy, Video | 2 | 2012 | 245 | 0.120 |
Why?
|
Polymorphism, Genetic | 4 | 2013 | 4328 | 0.120 |
Why?
|
Gestational Age | 1 | 2022 | 3493 | 0.120 |
Why?
|
T-Box Domain Proteins | 1 | 2016 | 471 | 0.120 |
Why?
|
Kinetics | 4 | 2022 | 6476 | 0.120 |
Why?
|
Autoimmunity | 1 | 2021 | 1350 | 0.110 |
Why?
|
Hypersensitivity | 1 | 2022 | 1102 | 0.110 |
Why?
|
Infant, Newborn, Diseases | 1 | 2019 | 582 | 0.110 |
Why?
|
Asymptomatic Diseases | 1 | 2016 | 551 | 0.110 |
Why?
|
Proviruses | 1 | 2015 | 318 | 0.110 |
Why?
|
Phenotype | 8 | 2022 | 16367 | 0.110 |
Why?
|
Antitubercular Agents | 1 | 2021 | 1320 | 0.110 |
Why?
|
Salmonella Infections | 1 | 2014 | 173 | 0.110 |
Why?
|
Apyrase | 1 | 2015 | 364 | 0.110 |
Why?
|
Receptors, Immunologic | 2 | 2011 | 1423 | 0.110 |
Why?
|
Point Mutation | 2 | 2018 | 1624 | 0.110 |
Why?
|
Early Diagnosis | 1 | 2018 | 1184 | 0.110 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2015 | 442 | 0.110 |
Why?
|
B-Cell Activating Factor | 1 | 2013 | 119 | 0.110 |
Why?
|
Antiviral Agents | 3 | 2020 | 2987 | 0.110 |
Why?
|
Signal Transduction | 5 | 2019 | 23404 | 0.110 |
Why?
|
Proteomics | 3 | 2021 | 3638 | 0.110 |
Why?
|
Chemokine CCL4 | 1 | 2012 | 129 | 0.100 |
Why?
|
Salmonella typhimurium | 1 | 2014 | 351 | 0.100 |
Why?
|
Glycomics | 1 | 2013 | 123 | 0.100 |
Why?
|
Maternal Exposure | 1 | 2019 | 961 | 0.100 |
Why?
|
Influenza A Virus, H1N1 Subtype | 2 | 2019 | 459 | 0.100 |
Why?
|
Receptors, KIR2DL2 | 1 | 2011 | 7 | 0.100 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1178 | 0.100 |
Why?
|
Receptors, Interleukin-8A | 1 | 2011 | 44 | 0.100 |
Why?
|
Staphylococcal Infections | 1 | 2021 | 1400 | 0.100 |
Why?
|
Bacterial Toxins | 1 | 2017 | 931 | 0.100 |
Why?
|
Molecular Sequence Data | 10 | 2015 | 18111 | 0.100 |
Why?
|
Intestines | 1 | 2021 | 1924 | 0.100 |
Why?
|
Haplotypes | 2 | 2016 | 2779 | 0.100 |
Why?
|
Natural Cytotoxicity Triggering Receptor 3 | 1 | 2010 | 11 | 0.100 |
Why?
|
Longitudinal Studies | 8 | 2023 | 13991 | 0.100 |
Why?
|
Infection Control | 1 | 2018 | 965 | 0.100 |
Why?
|
Lymphopoiesis | 1 | 2012 | 135 | 0.100 |
Why?
|
Fibrosis | 1 | 2018 | 2029 | 0.100 |
Why?
|
Chemokines | 1 | 2015 | 970 | 0.100 |
Why?
|
Citrate (si)-Synthase | 1 | 1990 | 42 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1782 | 0.100 |
Why?
|
Goals | 1 | 2016 | 707 | 0.090 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1596 | 0.090 |
Why?
|
Adenoviruses, Human | 1 | 2012 | 257 | 0.090 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 162 | 0.090 |
Why?
|
Receptors, CXCR5 | 3 | 2017 | 92 | 0.090 |
Why?
|
Vagina | 1 | 2016 | 825 | 0.090 |
Why?
|
Microfluidics | 1 | 2016 | 662 | 0.090 |
Why?
|
Inflammation Mediators | 2 | 2017 | 1888 | 0.090 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2010 | 57 | 0.090 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2011 | 197 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2020 | 5077 | 0.090 |
Why?
|
Bacterial Load | 2 | 2021 | 153 | 0.090 |
Why?
|
Potassium Channels, Inwardly Rectifying | 1 | 2011 | 150 | 0.090 |
Why?
|
Uridine | 2 | 2007 | 146 | 0.090 |
Why?
|
Enzyme-Linked Immunospot Assay | 3 | 2016 | 130 | 0.090 |
Why?
|
Mutation | 6 | 2020 | 29786 | 0.090 |
Why?
|
Homeostasis | 1 | 2021 | 3339 | 0.090 |
Why?
|
Jurkat Cells | 3 | 2018 | 743 | 0.090 |
Why?
|
Communicable Disease Control | 1 | 2016 | 856 | 0.090 |
Why?
|
Double-Blind Method | 7 | 2021 | 12025 | 0.090 |
Why?
|
Decision Trees | 1 | 2011 | 506 | 0.090 |
Why?
|
DNA | 2 | 2021 | 7294 | 0.090 |
Why?
|
Weight Loss | 1 | 2021 | 2625 | 0.090 |
Why?
|
Substance Abuse, Intravenous | 1 | 2014 | 525 | 0.090 |
Why?
|
Animal Welfare | 2 | 2019 | 22 | 0.090 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2016 | 828 | 0.080 |
Why?
|
Cell Movement | 2 | 2011 | 5218 | 0.080 |
Why?
|
Stem Cells | 2 | 2019 | 3567 | 0.080 |
Why?
|
HIV Seronegativity | 2 | 2024 | 211 | 0.080 |
Why?
|
Immunization Schedule | 2 | 2020 | 221 | 0.080 |
Why?
|
Preservation, Biological | 1 | 2008 | 25 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2949 | 0.080 |
Why?
|
Biological Products | 1 | 2018 | 860 | 0.080 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2104 | 0.080 |
Why?
|
Phylogeny | 4 | 2021 | 2804 | 0.080 |
Why?
|
Solubility | 1 | 2010 | 1088 | 0.080 |
Why?
|
Receptors, Chemokine | 1 | 2011 | 670 | 0.080 |
Why?
|
Protein Isoforms | 1 | 2013 | 1730 | 0.080 |
Why?
|
GPI-Linked Proteins | 1 | 2009 | 435 | 0.080 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15078 | 0.080 |
Why?
|
Treatment Outcome | 10 | 2020 | 63107 | 0.080 |
Why?
|
Phlebotomy | 1 | 2008 | 141 | 0.080 |
Why?
|
Massachusetts | 4 | 2020 | 8662 | 0.080 |
Why?
|
Research | 1 | 2016 | 1999 | 0.080 |
Why?
|
Genes, MHC Class I | 2 | 2006 | 258 | 0.080 |
Why?
|
Cell Differentiation | 3 | 2018 | 11486 | 0.080 |
Why?
|
Gene Expression Regulation | 4 | 2018 | 12073 | 0.070 |
Why?
|
Lectins, C-Type | 1 | 2010 | 589 | 0.070 |
Why?
|
Nasal Mucosa | 2 | 2020 | 373 | 0.070 |
Why?
|
Skin | 1 | 2021 | 4372 | 0.070 |
Why?
|
Interleukin-17 | 2 | 2016 | 901 | 0.070 |
Why?
|
Sepsis | 1 | 2021 | 2593 | 0.070 |
Why?
|
Toll-Like Receptor 8 | 1 | 2007 | 90 | 0.070 |
Why?
|
Hepacivirus | 1 | 2014 | 1379 | 0.070 |
Why?
|
Interferons | 2 | 2021 | 706 | 0.070 |
Why?
|
Kenya | 2 | 2020 | 685 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2020 | 193 | 0.070 |
Why?
|
Genetic Variation | 3 | 2016 | 6542 | 0.070 |
Why?
|
Cell Proliferation | 3 | 2012 | 10483 | 0.070 |
Why?
|
Macrophages | 3 | 2018 | 5660 | 0.070 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2006 | 130 | 0.070 |
Why?
|
Interleukin-12 | 1 | 2008 | 580 | 0.070 |
Why?
|
Clonal Anergy | 1 | 2006 | 169 | 0.070 |
Why?
|
DNA Primers | 1 | 2010 | 2891 | 0.070 |
Why?
|
Mass Spectrometry | 1 | 2013 | 2204 | 0.070 |
Why?
|
Lymphocytes | 3 | 2023 | 2617 | 0.070 |
Why?
|
Regression Analysis | 3 | 2020 | 6459 | 0.070 |
Why?
|
HLA-A Antigens | 2 | 2005 | 232 | 0.070 |
Why?
|
Lymphocytic choriomeningitis virus | 2 | 2016 | 168 | 0.060 |
Why?
|
United States | 7 | 2022 | 69872 | 0.060 |
Why?
|
Tanzania | 2 | 2024 | 1346 | 0.060 |
Why?
|
Mutation, Missense | 2 | 2018 | 2566 | 0.060 |
Why?
|
Proteins | 1 | 2020 | 6100 | 0.060 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 1970 | 0.060 |
Why?
|
HLA-A2 Antigen | 1 | 2005 | 213 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2018 | 2736 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1862 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2021 | 57776 | 0.060 |
Why?
|
Vesiculovirus | 1 | 2023 | 50 | 0.060 |
Why?
|
Genes, Viral | 1 | 2005 | 718 | 0.060 |
Why?
|
Vaccines, Combined | 1 | 2023 | 69 | 0.060 |
Why?
|
Diarrhea | 2 | 2023 | 1348 | 0.060 |
Why?
|
Monkeypox virus | 1 | 2023 | 48 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2015 | 3024 | 0.060 |
Why?
|
Incidence | 2 | 2019 | 20952 | 0.060 |
Why?
|
Base Sequence | 2 | 2016 | 12797 | 0.060 |
Why?
|
Antigens, Helminth | 1 | 2023 | 64 | 0.060 |
Why?
|
Histocompatibility Antigens | 1 | 2004 | 471 | 0.060 |
Why?
|
Chromosome Mapping | 1 | 2012 | 4740 | 0.060 |
Why?
|
Gene Expression Profiling | 3 | 2019 | 9445 | 0.060 |
Why?
|
Biopsy | 2 | 2014 | 6755 | 0.060 |
Why?
|
Virulence | 2 | 2022 | 1333 | 0.060 |
Why?
|
DNA Copy Number Variations | 1 | 2011 | 1941 | 0.060 |
Why?
|
Major Histocompatibility Complex | 1 | 2006 | 936 | 0.060 |
Why?
|
Immunoglobulin Allotypes | 1 | 2022 | 56 | 0.050 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2007 | 571 | 0.050 |
Why?
|
Open Reading Frames | 1 | 2006 | 811 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4034 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2011 | 4185 | 0.050 |
Why?
|
Mice, Knockout | 4 | 2023 | 14561 | 0.050 |
Why?
|
Virosomes | 1 | 2022 | 5 | 0.050 |
Why?
|
Models, Biological | 4 | 2021 | 9584 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 29060 | 0.050 |
Why?
|
Schistosoma mansoni | 1 | 2023 | 149 | 0.050 |
Why?
|
Measles virus | 1 | 2022 | 68 | 0.050 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2022 | 62 | 0.050 |
Why?
|
Hepatitis Delta Virus | 1 | 2021 | 18 | 0.050 |
Why?
|
Protein Conformation | 3 | 2020 | 4010 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2022 | 193 | 0.050 |
Why?
|
Encephalomyelitis, Equine | 1 | 2021 | 7 | 0.050 |
Why?
|
Comorbidity | 3 | 2021 | 10388 | 0.050 |
Why?
|
Encephalitis Virus, Eastern Equine | 1 | 2021 | 9 | 0.050 |
Why?
|
Measles Vaccine | 1 | 2022 | 76 | 0.050 |
Why?
|
Mice, Transgenic | 3 | 2020 | 9735 | 0.050 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2022 | 150 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 4751 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2010 | 2259 | 0.050 |
Why?
|
alpha-Crystallins | 1 | 2020 | 4 | 0.050 |
Why?
|
Drug Carriers | 2 | 2018 | 693 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7182 | 0.050 |
Why?
|
Bangladesh | 1 | 2023 | 687 | 0.050 |
Why?
|
Gene Order | 1 | 2021 | 176 | 0.050 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2023 | 401 | 0.050 |
Why?
|
Horses | 1 | 2021 | 304 | 0.050 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2018 | 1723 | 0.050 |
Why?
|
U937 Cells | 1 | 2020 | 268 | 0.050 |
Why?
|
Sequence Analysis, RNA | 2 | 2020 | 2012 | 0.040 |
Why?
|
Peptide Library | 1 | 2021 | 349 | 0.040 |
Why?
|
Administration, Intranasal | 1 | 2021 | 446 | 0.040 |
Why?
|
Age Factors | 3 | 2021 | 18373 | 0.040 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2021 | 708 | 0.040 |
Why?
|
Antigenic Variation | 2 | 2012 | 125 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 7914 | 0.040 |
Why?
|
Joints | 1 | 2021 | 327 | 0.040 |
Why?
|
Reference Values | 1 | 2007 | 4982 | 0.040 |
Why?
|
Drug Resistance, Multiple | 1 | 2020 | 252 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 323 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15160 | 0.040 |
Why?
|
Filoviridae Infections | 1 | 2019 | 6 | 0.040 |
Why?
|
CD40 Ligand | 1 | 2021 | 526 | 0.040 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2019 | 24 | 0.040 |
Why?
|
Lymphoid Tissue | 1 | 2021 | 455 | 0.040 |
Why?
|
Permeability | 1 | 2021 | 738 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 12746 | 0.040 |
Why?
|
Molecular Mimicry | 1 | 2020 | 201 | 0.040 |
Why?
|
Immunogenetic Phenomena | 1 | 2018 | 23 | 0.040 |
Why?
|
Adenoviruses, Simian | 1 | 2018 | 14 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5692 | 0.040 |
Why?
|
Complement C1q | 1 | 2019 | 92 | 0.040 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2019 | 106 | 0.040 |
Why?
|
Pteridines | 1 | 2018 | 45 | 0.040 |
Why?
|
Inhibitory Concentration 50 | 1 | 2019 | 459 | 0.040 |
Why?
|
Macrophages, Alveolar | 1 | 2021 | 407 | 0.040 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2021 | 548 | 0.040 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2022 | 615 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
Malawi | 1 | 2019 | 282 | 0.040 |
Why?
|
Friend murine leukemia virus | 1 | 2017 | 65 | 0.040 |
Why?
|
Immune Sera | 1 | 2018 | 641 | 0.040 |
Why?
|
Coronavirus | 1 | 2020 | 158 | 0.040 |
Why?
|
Mutant Proteins | 1 | 2020 | 500 | 0.040 |
Why?
|
ABO Blood-Group System | 1 | 2020 | 367 | 0.040 |
Why?
|
Saliva | 1 | 2022 | 809 | 0.040 |
Why?
|
Virus Attachment | 1 | 2018 | 55 | 0.040 |
Why?
|
Neonatal Screening | 1 | 2022 | 591 | 0.040 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2022 | 428 | 0.040 |
Why?
|
Rats, Wistar | 1 | 2021 | 1892 | 0.040 |
Why?
|
Nose | 1 | 2021 | 509 | 0.040 |
Why?
|
Algorithms | 1 | 2018 | 13882 | 0.040 |
Why?
|
Retroviridae Infections | 1 | 2017 | 151 | 0.040 |
Why?
|
Virus Internalization | 1 | 2021 | 502 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2016 | 3921 | 0.040 |
Why?
|
Mammals | 1 | 2023 | 1143 | 0.040 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 25039 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2022 | 6171 | 0.040 |
Why?
|
Pregnadienes | 1 | 1996 | 24 | 0.040 |
Why?
|
Aspartate Aminotransferases | 1 | 2018 | 418 | 0.040 |
Why?
|
Survival Analysis | 2 | 2020 | 10252 | 0.040 |
Why?
|
Orthomyxoviridae Infections | 1 | 2019 | 248 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2019 | 915 | 0.040 |
Why?
|
Binding Sites, Antibody | 1 | 2017 | 349 | 0.040 |
Why?
|
3T3 Cells | 1 | 2018 | 1101 | 0.040 |
Why?
|
Convalescence | 1 | 2016 | 105 | 0.040 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2021 | 2556 | 0.040 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 546 | 0.040 |
Why?
|
Sequence Analysis, DNA | 3 | 2016 | 4805 | 0.030 |
Why?
|
Developed Countries | 1 | 2019 | 437 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12244 | 0.030 |
Why?
|
Biological Evolution | 1 | 2022 | 1077 | 0.030 |
Why?
|
Enterotoxins | 1 | 2017 | 368 | 0.030 |
Why?
|
Cross Protection | 1 | 2015 | 24 | 0.030 |
Why?
|
Arenaviridae Infections | 1 | 2015 | 51 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1851 | 0.030 |
Why?
|
Oligopeptides | 1 | 2021 | 1189 | 0.030 |
Why?
|
Workplace | 1 | 2022 | 836 | 0.030 |
Why?
|
Dizziness | 1 | 2018 | 251 | 0.030 |
Why?
|
CHO Cells | 1 | 2018 | 1409 | 0.030 |
Why?
|
Interleukin-6 | 2 | 2020 | 3203 | 0.030 |
Why?
|
Amniotic Fluid | 1 | 2017 | 370 | 0.030 |
Why?
|
Lectins | 1 | 2018 | 513 | 0.030 |
Why?
|
Puerto Rico | 1 | 2016 | 356 | 0.030 |
Why?
|
Prednisolone | 1 | 1996 | 334 | 0.030 |
Why?
|
Parturition | 1 | 2019 | 441 | 0.030 |
Why?
|
HIV Long Terminal Repeat | 1 | 2015 | 88 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2021 | 1461 | 0.030 |
Why?
|
Transgenes | 1 | 2018 | 1009 | 0.030 |
Why?
|
Temperature | 1 | 2021 | 2204 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2023 | 77460 | 0.030 |
Why?
|
Toll-Like Receptor 4 | 1 | 2018 | 565 | 0.030 |
Why?
|
Sex Factors | 2 | 2019 | 10400 | 0.030 |
Why?
|
Program Development | 1 | 2021 | 1316 | 0.030 |
Why?
|
Organizational Objectives | 1 | 2016 | 438 | 0.030 |
Why?
|
Back Pain | 1 | 2018 | 545 | 0.030 |
Why?
|
Spleen | 1 | 2020 | 2362 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1025 | 0.030 |
Why?
|
Brain | 1 | 2021 | 26388 | 0.030 |
Why?
|
Sequence Analysis, Protein | 1 | 2015 | 258 | 0.030 |
Why?
|
Dependovirus | 1 | 2018 | 706 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2013 | 226 | 0.030 |
Why?
|
Drug Combinations | 1 | 2019 | 1958 | 0.030 |
Why?
|
HIV Seroprevalence | 1 | 2013 | 86 | 0.030 |
Why?
|
DNA-Binding Proteins | 2 | 2012 | 9647 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2018 | 1793 | 0.030 |
Why?
|
Protein Stability | 1 | 2015 | 556 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2018 | 733 | 0.030 |
Why?
|
Crystallography, X-Ray | 1 | 2018 | 2012 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 881 | 0.030 |
Why?
|
Uveitis | 1 | 1996 | 375 | 0.030 |
Why?
|
Immunity, Mucosal | 1 | 2016 | 490 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2021 | 1453 | 0.030 |
Why?
|
Cattle | 1 | 2018 | 3922 | 0.030 |
Why?
|
Africa | 1 | 2014 | 672 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2016 | 2256 | 0.030 |
Why?
|
Brazil | 1 | 2016 | 1270 | 0.030 |
Why?
|
Interleukin-2 | 2 | 2012 | 1904 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2021 | 2418 | 0.030 |
Why?
|
Immunologic Tests | 1 | 2012 | 103 | 0.030 |
Why?
|
Lung Diseases, Interstitial | 1 | 2020 | 808 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2018 | 1064 | 0.030 |
Why?
|
Transfection | 2 | 2011 | 5895 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2021 | 1771 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2015 | 1005 | 0.030 |
Why?
|
Random Allocation | 1 | 2016 | 2428 | 0.020 |
Why?
|
Contraception | 1 | 2015 | 359 | 0.020 |
Why?
|
Cell Line, Tumor | 3 | 2016 | 16690 | 0.020 |
Why?
|
Immunoglobulin Variable Region | 1 | 2012 | 421 | 0.020 |
Why?
|
Canarypox virus | 1 | 2011 | 10 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2013 | 17446 | 0.020 |
Why?
|
Fatigue | 1 | 2018 | 1531 | 0.020 |
Why?
|
Recurrence | 2 | 2020 | 8340 | 0.020 |
Why?
|
ras Proteins | 1 | 2016 | 1060 | 0.020 |
Why?
|
Drosophila | 1 | 2018 | 1491 | 0.020 |
Why?
|
Receptors, KIR2DL1 | 1 | 2010 | 15 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2013 | 767 | 0.020 |
Why?
|
Genetic Engineering | 1 | 2016 | 951 | 0.020 |
Why?
|
Hydrogen Bonding | 1 | 1990 | 291 | 0.020 |
Why?
|
Receptors, CXCR4 | 1 | 2015 | 727 | 0.020 |
Why?
|
Receptors, HIV | 1 | 2010 | 163 | 0.020 |
Why?
|
Income | 1 | 2019 | 1913 | 0.020 |
Why?
|
Melanoma | 1 | 2008 | 5511 | 0.020 |
Why?
|
Fetus | 1 | 2017 | 1880 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2951 | 0.020 |
Why?
|
International Cooperation | 1 | 2016 | 1420 | 0.020 |
Why?
|
Histidine | 1 | 1990 | 313 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6489 | 0.020 |
Why?
|
Homozygote | 1 | 2014 | 1787 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2015 | 2088 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1990 | 1085 | 0.020 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 39 | 0.020 |
Why?
|
MART-1 Antigen | 1 | 2008 | 64 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
Catalysis | 1 | 1990 | 762 | 0.020 |
Why?
|
Drosophila melanogaster | 1 | 2018 | 1708 | 0.020 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 153 | 0.020 |
Why?
|
Imidazoles | 1 | 2015 | 1206 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2021 | 4463 | 0.020 |
Why?
|
Risk-Taking | 1 | 2014 | 986 | 0.020 |
Why?
|
Interleukin-5 | 1 | 2008 | 273 | 0.020 |
Why?
|
Aspartic Acid | 1 | 1990 | 576 | 0.020 |
Why?
|
Immunomagnetic Separation | 1 | 2008 | 80 | 0.020 |
Why?
|
Receptors, CCR4 | 1 | 2008 | 81 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3646 | 0.020 |
Why?
|
Health Status | 1 | 2021 | 4034 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2018 | 2916 | 0.020 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2008 | 202 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2008 | 232 | 0.020 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2008 | 140 | 0.020 |
Why?
|
Educational Status | 1 | 2015 | 2540 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13409 | 0.020 |
Why?
|
Receptors, Interleukin | 1 | 2008 | 245 | 0.020 |
Why?
|
Nanotechnology | 1 | 2012 | 710 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2014 | 2216 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2715 | 0.020 |
Why?
|
Hospitals | 1 | 2020 | 3954 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 1996 | 1790 | 0.020 |
Why?
|
Transcription Factors | 1 | 2006 | 12207 | 0.020 |
Why?
|
NF-kappa B | 1 | 2015 | 2499 | 0.020 |
Why?
|
Virus Shedding | 1 | 2006 | 108 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10943 | 0.020 |
Why?
|
Gene Products, vpr | 1 | 2005 | 36 | 0.020 |
Why?
|
vpr Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 39 | 0.020 |
Why?
|
Computer Simulation | 1 | 2019 | 6194 | 0.020 |
Why?
|
Endosomal Sorting Complexes Required for Transport | 1 | 2006 | 144 | 0.020 |
Why?
|
Research Design | 1 | 2021 | 5984 | 0.020 |
Why?
|
Rats | 1 | 2021 | 24252 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2011 | 4320 | 0.020 |
Why?
|
Consensus Sequence | 1 | 2005 | 378 | 0.020 |
Why?
|
Progesterone | 1 | 2009 | 775 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2018 | 5023 | 0.020 |
Why?
|
Societies, Medical | 1 | 2016 | 3743 | 0.010 |
Why?
|
Oligonucleotides | 1 | 2007 | 572 | 0.010 |
Why?
|
Body Mass Index | 1 | 2021 | 12721 | 0.010 |
Why?
|
Linear Models | 1 | 2014 | 5953 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2703 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 1677 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5749 | 0.010 |
Why?
|
Caspase 3 | 1 | 2004 | 758 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 12802 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2023 | 15297 | 0.010 |
Why?
|
Species Specificity | 1 | 2005 | 2478 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2008 | 3848 | 0.010 |
Why?
|
Caspases | 1 | 2004 | 928 | 0.010 |
Why?
|
Odds Ratio | 1 | 2013 | 9849 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2008 | 1988 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7282 | 0.010 |
Why?
|
Swine | 1 | 1990 | 5918 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2008 | 1678 | 0.010 |
Why?
|
Substrate Specificity | 1 | 2004 | 1802 | 0.010 |
Why?
|
Diet | 1 | 2017 | 7937 | 0.010 |
Why?
|
Escherichia coli | 1 | 1990 | 4217 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 23336 | 0.010 |
Why?
|
Suspensions | 1 | 1996 | 65 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 5867 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2008 | 3707 | 0.010 |
Why?
|
Anterior Chamber | 1 | 1996 | 197 | 0.010 |
Why?
|
Ophthalmic Solutions | 1 | 1996 | 317 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 72296 | 0.010 |
Why?
|
Administration, Topical | 1 | 1996 | 690 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 12356 | 0.010 |
Why?
|
Safety | 1 | 1996 | 1186 | 0.010 |
Why?
|
Intraocular Pressure | 1 | 1996 | 1270 | 0.010 |
Why?
|